An overwhelming majority of the audience at an RSNA special focus session Thursday voted in favor of keeping up the efforts to get FDA approval for the use of contrast ultrasound for general radiology applications.
An overwhelming majority of the audience at an RSNA special focus session Thursday voted in favor of keeping up the efforts to get FDA approval for the use of contrast ultrasound for general radiology applications.
When moderator Dr. Peter N. Burns asked those in the 200-plus crowd to raise their hands if they thought the plug should not be pulled on ultrasound contrast, not more than a dozen physicians kept theirs down. When Burns asked to see the hands of those who thought contrast should be let go, only one went up.
A panel composed of Drs. Burns and Stephanie R. Wilson from Canada, Luigi Solbiati from Italy, and Myron A. Pozniak from Madison, WI, discussed the regulatory approval status for contrast-enhanced sonography around the world, its clinical applications, and the arguments in favor of and against the technique.
After the panel discussion and the symbolic voting, members of the audience shared commentaries. Most agreed that the technique is useful and valuable in multiple imaging subspecialties: musculoskeletal, ob/gyn, cardiovascular, and interventional radiology, to name only a few. They also agreed, however, that the reimbursement landscape in the U.S. overwhelmingly favors CT and MR imaging over sonography, which is still considered a time-consuming and operator-dependent modality.
Many said the choice is inevitable. But it could also be harmful to radiology.
"The FDA does not get any benefit from saying 'yes' and having a complication or something negative occur. And there is no cost to them to saying 'no.' The constituency for this is outside radiology," an audience member said. "But then everybody else will end up doing ultrasound and in the future radiologists will be relegated to the sidelines by other subspecialists, who will be doing diagnostic studies using contrast ultrasound."
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Multicenter Study Shows Merits of AI-Powered Ultrasound Assessment for Detecting Ovarian Cancer
January 3rd 2025Adjunctive AI offered greater than seven percent increases in sensitivity, specificity, and accuracy for ultrasound detection of ovarian cancer in comparison to unassisted clinicians who lacked ultrasound expertise, according to findings from new international multicenter research.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.